Wall Street analysts predict that Core Laboratories (NYSE:CLB) will post sales of $178.72 million for the current fiscal quarter, according to Zacks Investment Research. Two analysts have issued estimates for Core Laboratories’ earnings, with the highest sales estimate coming in at $179.43 million and the lowest estimate coming in at $178.00 million. Core Laboratories posted sales of $166.25 million in the same quarter last year, which indicates a positive year over year growth rate of 7.5%. The firm is expected to report its next quarterly earnings report on Monday, October 22nd.

According to Zacks, analysts expect that Core Laboratories will report full-year sales of $703.81 million for the current financial year, with estimates ranging from $703.00 million to $704.62 million. For the next financial year, analysts expect that the company will report sales of $787.21 million per share, with estimates ranging from $777.00 million to $797.41 million. Zacks’ sales averages are a mean average based on a survey of research firms that follow Core Laboratories.

Core Laboratories (NYSE:CLB) last announced its earnings results on Wednesday, July 25th. The oil and gas company reported $0.59 earnings per share (EPS) for the quarter, meeting the Zacks’ consensus estimate of $0.59. The firm had revenue of $175.48 million during the quarter, compared to analyst estimates of $174.47 million. Core Laboratories had a net margin of 13.32% and a return on equity of 64.13%. Core Laboratories’s revenue was up 10.9% compared to the same quarter last year. During the same quarter in the prior year, the firm posted $0.51 EPS.

A number of equities analysts recently issued reports on the stock. Piper Jaffray Companies reiterated a “hold” rating and issued a $96.00 target price on shares of Core Laboratories in a research report on Friday, July 27th. JPMorgan Chase & Co. reduced their price objective on shares of Core Laboratories from $121.00 to $118.00 and set an “overweight” rating for the company in a research note on Friday, July 27th. Citigroup raised shares of Core Laboratories from a “sell” rating to a “neutral” rating and set a $117.00 price objective for the company in a research note on Monday, August 13th. ValuEngine raised shares of Core Laboratories from a “hold” rating to a “buy” rating in a research note on Thursday, May 17th. Finally, Zacks Investment Research lowered shares of Core Laboratories from a “hold” rating to a “sell” rating in a research note on Wednesday, July 4th. Two analysts have rated the stock with a sell rating, seven have given a hold rating and four have issued a buy rating to the stock. Core Laboratories currently has an average rating of “Hold” and an average price target of $114.90.

A number of large investors have recently added to or reduced their stakes in CLB. Fisher Asset Management LLC acquired a new position in Core Laboratories in the first quarter worth approximately $47,402,000. Massachusetts Financial Services Co. MA increased its holdings in Core Laboratories by 24.5% in the first quarter. Massachusetts Financial Services Co. MA now owns 1,787,251 shares of the oil and gas company’s stock worth $193,416,000 after buying an additional 351,847 shares during the last quarter. WCM Investment Management CA increased its holdings in Core Laboratories by 5.1% in the first quarter. WCM Investment Management CA now owns 5,035,827 shares of the oil and gas company’s stock worth $544,977,000 after buying an additional 242,096 shares during the last quarter. Millennium Management LLC increased its holdings in Core Laboratories by 9,329.6% in the second quarter. Millennium Management LLC now owns 226,594 shares of the oil and gas company’s stock worth $28,598,000 after buying an additional 224,191 shares during the last quarter. Finally, Sei Investments Co. increased its holdings in Core Laboratories by 40.1% in the first quarter. Sei Investments Co. now owns 638,723 shares of the oil and gas company’s stock worth $69,123,000 after buying an additional 182,848 shares during the last quarter.

Shares of CLB opened at $115.28 on Wednesday. The stock has a market capitalization of $5.04 billion, a P/E ratio of 58.46 and a beta of 1.44. The company has a debt-to-equity ratio of 1.53, a current ratio of 2.24 and a quick ratio of 1.85. Core Laboratories has a 52-week low of $86.55 and a 52-week high of $130.34.

The company also recently disclosed a quarterly dividend, which was paid on Monday, August 13th. Investors of record on Monday, July 23rd were issued a $0.55 dividend. The ex-dividend date was Friday, July 20th. This represents a $2.20 dividend on an annualized basis and a yield of 1.91%. Core Laboratories’s dividend payout ratio is currently 110.00%.

About Core Laboratories

Core Laboratories N.V. provides reservoir description, and production enhancement services and products to the oil and gas industry in the United States, Canada, and internationally. It operates in two segments, Reservoir Description and Production Enhancement segments. The Reservoir Description segment comprises the characterization of petroleum reservoir rock, fluid, and gas samples to enhance production and improve recovery of oil and gas from its clients' reservoirs.

See Also: Fundamental Analysis – How It Helps Investors

Get a free copy of the Zacks research report on Core Laboratories (CLB)

For more information about research offerings from Zacks Investment Research, visit Zacks.com

Earnings History and Estimates for Core Laboratories (NYSE:CLB)

Receive News & Ratings for Core Laboratories Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Core Laboratories and related companies with MarketBeat.com's FREE daily email newsletter.